Peter B. Johansen
Biography & Research Background
Peter B. Johansen is a researcher at Novo Nordisk (Department of Pharmacological Research). Johansen's research focused on the pharmacokinetics of Ipamorelin, specifically evaluating its bioavailability through different administration routes — intravenous, subcutaneous, intranasal (~20% bioavailability), and oral (<1%). He demonstrated that Ipamorelin induces dose-dependent longitudinal bone growth in adult rats (42→52 µm/day, p<0.0001 over 15 days of treatment). Key publications include 'Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption' (Xenobiotica, 1998) and 'Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats' (Growth Hormone & IGF Research, 1999). Peter B. Johansen is referenced as a leading scientist in Ipamorelin research. In no way is this scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this scientist.
External Profiles
Authored Research Profiles (1)
Peter B. Johansen is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Peter B. Johansen is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.